Journals / Anestezi Dergisi / 2015 / Cilt: 23 - Sayı: 4

MYASTENIA GRAVIS AND ANESTHESIA MANAGEMENT

MİYASTENİA GRAVİS VE ANESTEZİ YÖNETİMİ

Pages
201–205
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we aimed to increase awareness of the clinicians about the anesthetic approach to the management of MG disease

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Myasthenia Gravis (MG) is a muscle disease affecting the neuromuscular junction and characterised by weakness of skeletal muscle.
📊
Key Findings & Data:Although, MG is rarely in society, it is a special research area for the clinicians and one of the important headings which anesthesiologists interested in.
💡
Conclusion & Impact:In this review, we aimed to increase awareness of the clinicians about the anesthetic approach to the management of MG disease
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Myasthenia Gravis (MG) is a muscle disease affecting the neuromuscular junction and characterised by weakness of skeletal muscle. Although, MG is rarely in society, it is a special research area for the clinicians and one of the important headings which anesthesiologists interested in. Nowadays the disease still have a challenge in the anesthesiology community because the pathophysiological consequences of the disease are closely associated with to many drugs like muscle relaxants. The mechanism and the management of the disease which is also triggered by stress factors, should have particularly known by all the anesthesiologists, because of the risk of postoperative respiratory failure. In this review, we aimed to increase awareness of the clinicians about the anesthetic approach to the management of MG disease

Özet

Miyastenia Gravis (MG) nöromusküler kavflağı tutan ve çizgili kaslarda güçsüzlüğe neden olan bir kas hastalığı türüdür. Toplumda nadir görülse de bu hastalığın ortaya çıkardığı patofizyolojik değiflimlerin kas gevfleticiler ve pek çok ilaç ile yakın iliflkili olması gibi nedenlerle MG anestezistlerin gündeminden düflmeyen özel bir durumdur. Stresle de tetiklenebilen bu hastalığın postoperati f solunum yetmezliği gelifltirme riski bulunması nedeniyle mekanizmasının ve yönetiminin tüm anestezi uygulayıcıları tarafından ayrıntılı olarak bilinmesi gerekmektedir. Bu derlemede MG hastalığının yönetiminde anestezik yaklaflımlara ıflık tutmak ve farkındalığın arttırılması amaçlanmıfltır.

🔖

Cite This Article

ŞENTÜRK, B. Ç., KIZILAY, D., SARAÇOĞLU, A., KAYALI, İ. H. (2015). MYASTENIA GRAVIS AND ANESTHESIA MANAGEMENT. Anestezi Dergisi, Cilt: 23 - Sayı: 4, 201–205. https://ajindex.com/articles/153620

References (18)

  1. Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classification of autoimmune myastenia gravis. J Autoimmun 2014; 48-49: 143-148
  2. Gilhus NE. Myastenia and the neuromuscular junction. Curr Opin Neurol 2012; 25: 523-529
  3. Gonseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myastenia gravis. Neurology 2000; 55: 7-15
  4. Carr AS, Cardwell CR, McCarron PO, McConville J. A systemic review of population based epidemiological studies in myastenia gravis. BMC Neurol 2010; 10: 10-46
  5. Huang X, Liu WB, Men LN, et al. Clinical features of myastenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci 2013; 34: 911-917
  6. Murai H, Yamashita N, Watanabe M et al. Chacteristics of myastenia gravis according to onset age: Japanese nationwide surve. J Neurol Sci 2011; 305: 97-102
  7. McGrogan A, Sneddon S, de Vries CS. The incidence of myastenia gravis: a systematic literature review. Neuroepidemiology 2010; 34: 171-183
  8. Lindstorm J. Acetylcholine receptors and myastenia. Muscle Nerve 2000; 23: 453-477
  9. Misgeld T, Kummer TT, Lichtman JW, Sanes JR. Agrin promotes synaptic differentiation by counteracting an inhibitory effect of neurotransmitter. Proc Natl Acad Sci USA 2005; 102: 11088-11093
  10. Motomura M, Narita Masuda T. Autoantibodies in myasthenia gravis. Brain Nerve 2013; 65: 433-439
  11. Gold R, Hohfeld R, Toyka KV. Progress in the treatment of myastenia gravis. Ther Adv Neurol Disord 2008; 1: 36-51
  12. Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myastenia gravis: a U.S. experience. Muscle Nerve 2010; 41: 370-374
  13. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: Report of 116 cases. Ann Neurol 1984; 15: 291-298
  14. Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis 2014; 15: 167-178
  15. Yamada Y, Yoshida S, Suzuki H, et al. Efficacy of perioperative high-dose prednisolone therapy during thymectomy in myastenia gravis patients. J Cardiothorac Surg 2013; 8: 226
  16. Sorgun MH, Sener HO, Yucesan C, Yucemen N. Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myastenia Gravis. Neurol Sci 2014; 35: 891-896
  17. Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myastenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis 2011; 13: 85-94
  18. Diaz A, Black E, Dunning J